In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Mutual fund boardrooms are more diverse than ever, with the percentage of women and individuals representing a racial or ethnic minority group increasing annually—and at a ...
Independent mutual fund directors earned more in 2022 than they did in 2021, according to industry data obtained by Fund Board Views. The year-on-year increase—a median of ...
Jay Baris, a partner in the Investment Funds group at Sidley Austin, has gotten into podcasting. The '40 Act lawyer is not just a podcast enthusiast, ...
The Securities and Exchange Commission's move away from swing pricing in the money market fund rule finalized last week was welcomed by the fund board community, ...